Robert F Gray, MD
Otolaryngology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 2
Offices
2 locations · County of Santa Clara · 1,000 clinicians in this group
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gray’s office at (888) 334-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G83766 · Current
Licensed to practise in California · since 1997 · expires 2029-01-31 · Saint Louis University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Tracy Surgery Center, LLC DBA Tracy Surgery CenterAmbulatory Surgery Center · Tracy, CA3.61% owner since 2006 · accredited by AAAHCAccreditation Renewed3 inspections, 1 with deficiencies · last 2023-06-28: Requirements Met
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$10,519
Medicare paid this office $10,519 for 72 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (30+ min) | 39 | $2,488 | $64 |
| Short return visit (20+ min) | 23 | $2,183 | $50 |
| Removal of impacted ear wax | 13 | $383 | $24 |
Who their Medicare patients are
72 Original Medicare patients in 2024. Average age 68 · Under 65 26% · 85 and older 18% · Women 51% · Health risk score 1.53. Above the middle of the specialty; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 72% · Diabetes 38% · COPD 21% · Depression 21% · Coronary heart disease 19% · Chronic kidney disease 19%.
The office billed $48,526, Medicare allowed $13,836 and paid $10,519; for 153 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 72 | 153 | 68 | 1.53 | $48,526 | $10,519 |
| 2023 | 84 | 143 | 68 | 1.84 | $40,541 | $8,976 |
| 2022 | 45 | 92 | 73 | 1.79 | $33,338 | $6,240 |
| 2021 | 52 | 100 | 69 | 1.43 | $27,504 | $7,266 |
| 2020 | 54 | 84 | 68 | 1.44 | $40,741 | $8,085 |
| 2019 | 256 | 655 | 74 | 1.35 | $118,292 | $38,430 |
| 2018 | 282 | 855 | 75 | 1.45 | $155,676 | $55,707 |
| 2017 | 283 | 837 | 75 | 1.78 | $142,038 | $54,191 |
| 2016 | 297 | 775 | 73 | 1.49 | $141,363 | $52,066 |
| 2015 | 277 | 728 | 74 | 1.76 | $200,786 | $51,071 |
| 2014 | 245 | 656 | 72 | 1.45 | $148,586 | $50,396 |
| 2013 | 287 | 817 | 73 | 1.42 | $163,748 | $62,420 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| New patient visit (30+ min) | 60 | $2,922 | $49 |
| Short return visit (20+ min) | 24 | $1,646 | $47 |
2022: 3 services
| New patient visit (30+ min) | 23 | $1,481 | $64 |
| Short return visit (20+ min) | 14 | $1,247 | $50 |
| Diagnostic exam of voice box using a flexible endoscope | 11 | $592 | $46 |
2021: 2 services
| New patient visit (30+ min) | 36 | $2,161 | $60 |
| Short return visit (20+ min) | 18 | $1,780 | $56 |
2020: 2 services
| New patient visit (30+ min) | 21 | $1,178 | $56 |
| Short return visit (20+ min) | 15 | $758 | $38 |
2019: 6 services
| Short return visit (20+ min) | 147 | $11,888 | $54 |
| New patient visit (30+ min) | 132 | $9,957 | $75 |
| Removal of impacted ear wax | 84 | $3,208 | $33 |
| Diagnostic exam of voice box using a flexible endoscope | 24 | $2,704 | $93 |
| Comprehensive hearing and speech recognition test | 40 | $1,154 | $29 |
| Test to assess middle ear function | 43 | $519 | $12 |
2018: 7 services
| Short return visit (20+ min) | 195 | $18,237 | $56 |
| New patient visit (30+ min) | 152 | $12,343 | $81 |
| Removal of impacted ear wax | 100 | $4,536 | $37 |
| Diagnostic exam of voice box using a flexible endoscope | 32 | $4,228 | $94 |
| Simple control of nose bleed | 13 | $1,788 | $105 |
| Comprehensive hearing and speech recognition test | 54 | $1,710 | $31 |
| Test to assess middle ear function | 58 | $719 | $12 |
2017: 7 services
| Short return visit (20+ min) | 196 | $17,495 | $57 |
| New patient visit (30+ min) | 162 | $13,649 | $84 |
| Diagnostic exam of voice box using a flexible endoscope | 39 | $4,231 | $92 |
| Removal of impacted ear wax | 81 | $3,825 | $37 |
| Comprehensive hearing and speech recognition test | 53 | $1,589 | $30 |
| Simple control of nose bleed | 15 | $1,313 | $73 |
| Test to assess middle ear function | 54 | $636 | $12 |
2016: 7 services
| Short return visit (20+ min) | 178 | $15,543 | $57 |
| New patient visit (30+ min) | 167 | $14,058 | $84 |
| Diagnostic exam of voice box using a flexible endoscope | 37 | $3,861 | $94 |
| Removal of impacted ear wax | 64 | $2,879 | $37 |
| Comprehensive hearing and speech recognition test | 52 | $1,580 | $30 |
| Test to assess middle ear function | 56 | $651 | $12 |
| Exam of ear using a microscope | 17 | $397 | $23 |
2015: 7 services
| Short return visit (20+ min) | 170 | $14,967 | $57 |
| New patient visit (30+ min) | 151 | $12,266 | $81 |
| Diagnostic exam of voice box using a flexible endoscope | 34 | $3,530 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,084 | $162 |
| Removal of impacted ear wax | 51 | $2,070 | $36 |
| Comprehensive hearing and speech recognition test | 49 | $1,304 | $27 |
| Test to assess middle ear function | 50 | $581 | $11 |
2014: 8 services
| Short return visit (20+ min) | 144 | $13,501 | $55 |
| New patient visit (30+ min) | 147 | $12,134 | $83 |
| New patient visit (45+ min) | 15 | $2,015 | $134 |
| Diagnostic exam of voice box using a flexible endoscope | 16 | $2,002 | $95 |
| Removal of impacted ear wax | 43 | $1,756 | $37 |
| Comprehensive hearing and speech recognition test | 35 | $992 | $28 |
| Simple control of nose bleed | 12 | $987 | $71 |
| Test to assess middle ear function | 37 | $432 | $11 |
2013: 8 services
| Short return visit (20+ min) | 158 | $14,935 | $57 |
| New patient visit (30+ min) | 178 | $14,473 | $81 |
| New patient visit (45+ min) | 34 | $4,538 | $133 |
| Diagnostic exam of voice box using a flexible endoscope | 26 | $3,364 | $96 |
| Removal of impacted ear wax | 62 | $3,255 | $40 |
| Simple control of nose bleed | 22 | $2,572 | $80 |
| Comprehensive hearing and speech recognition test | 50 | $1,532 | $31 |
| Test to assess middle ear function | 54 | $671 | $12 |
Medicaid work
$26,951 in 2024
Medicaid paid $26,951 for 425 billed services this clinician did in 2024, up to 32 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (30+ min) | 211 | $16,771 |
| Short return visit (20+ min) | 138 | $4,983 |
| Service | 17 | $2,541 |
| New patient visit (45+ min) | 12 | $1,258 |
| Service | 15 | $708 |
| Injection, propofol, 10 mg | 15 | $485 |
| Fentanyl citrate injection | 17 | $205 |
| 2024 | 425 | 7 | 32 | $26,951 |
| 2023 | 438 | 2 | 40 | $26,915 |
| 2022 | 275 | 2 | 26 | $14,499 |
| 2021 | 223 | 3 | 24 | $12,868 |
| 2020 | 83 | 2 | 15 | $3,318 |
| 2019 | 262 | 2 | 24 | $12,848 |
| 2018 | 453 | 3 | 29 | $26,342 |
See the largest Medicaid services in earlier years
2023
| New patient visit (30+ min) | 315 | $23,267 |
| Short return visit (20+ min) | 123 | $3,648 |
2022
| New patient visit (30+ min) | 161 | $11,332 |
| Short return visit (20+ min) | 114 | $3,168 |
2021
| New patient visit (30+ min) | 142 | $10,392 |
| Short return visit (20+ min) | 61 | $2,009 |
| Short return visit | 20 | $467 |
2020
| Short return visit (20+ min) | 69 | $2,242 |
| New patient visit (30+ min) | 14 | $1,077 |
2019
| New patient visit (30+ min) | 94 | $7,247 |
| Short return visit (20+ min) | 168 | $5,601 |
2018
| Short return visit (20+ min) | 282 | $11,078 |
| New patient visit (30+ min) | 122 | $11,069 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 49 | $4,195 |
Drugs they prescribed that Part D paid
$1,132
Pharmacies billed $1,132 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
68 generic and fewer than 11 brand-name prescriptions · $1,132 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Fluticasone Propionate | 11 | $241 | $12 |
| Nystatin | 12 | $151 | $12 |
Year by year
| 2024 | 69 | 36 | None | None | $1,132 |
| 2023 | 67 | 31 | None | 0% | $2,314 |
| 2022 | 55 | 23 | None | None | $864 |
| 2021 | 79 | 28 | None | None | $3,957 |
| 2020 | 61 | 31 | None | None | $887 |
| 2019 | 380 | 185 | None | None | $5,876 |
| 2018 | 494 | 202 | 2% (12) | 2% | $8,599 |
| 2017 | 544 | 227 | 2% (13) | 3% | $15,151 |
| 2016 | 517 | 216 | 3% (14) | None | $8,710 |
| 2015 | 494 | 216 | 2% (11) | 2% | $9,762 |
| 2014 | 483 | 236 | 5% (24) | None | $14,862 |
| 2013 | 469 | 253 | 4% (17) | 8% | $14,417 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Fluticasone Propionate | 17 | $513 | $30 |
| Omeprazole | 12 | $390 | $33 |
2021: 2 drugs
| Ofloxacin | 13 | $1,361 | $105 |
| Nystatin | 12 | $198 | $17 |
2020: 1 drug
| Fluticasone Propionate | 24 | $308 | $13 |
2019: 8 drugs
| Fluticasone Propionate | 81 | $1,082 | $13 |
| Nystatin | 59 | $690 | $12 |
| Neomycin-Polymyxin-Hc | 11 | $596 | $54 |
| Hydrocortisone | 61 | $341 | $6 |
| Acetic Acid | 11 | $259 | $24 |
| Famotidine | 16 | $184 | $12 |
| Prednisone | 33 | $142 | $4 |
| Omeprazole | 17 | $124 | $7 |
2018: 12 drugs
| Ofloxacin | 27 | $2,062 | $76 |
| Fluticasone Propionate | 123 | $1,574 | $13 |
| Neomycin-Polymyxin-Hc | 12 | $855 | $71 |
| Nystatin | 54 | $634 | $12 |
| Hydrocortisone | 63 | $358 | $6 |
| Acetic Acid | 15 | $357 | $24 |
| Amoxicillin-Clavulanate Potass | 14 | $206 | $15 |
| Prednisone | 42 | $145 | $3 |
| Famotidine | 12 | $133 | $11 |
| Omeprazole | 29 | $127 | $4 |
| Nortriptyline | 11 | $104 | $9 |
| Azithromycin | 11 | $100 | $9 |
2017: 11 drugs
| Ofloxacin | 36 | $6,863 | $191 |
| Fluticasone Propionate | 103 | $1,149 | $11 |
| Nystatin | 63 | $711 | $11 |
| Hydrocortisone | 71 | $438 | $6 |
| Omeprazole | 51 | $423 | $8 |
| Amoxicillin-Clavulanate Potass | 16 | $222 | $14 |
| Famotidine | 19 | $199 | $10 |
| Prednisone | 39 | $171 | $4 |
| Ciprofloxacin | 15 | $123 | $8 |
| Cephalexin | 14 | $99 | $7 |
| Hydrocodone-Acetaminophen | 11 | $68 | $6 |
2016: 7 drugs
| Fluticasone Propionate | 125 | $1,636 | $13 |
| Nystatin | 59 | $1,028 | $17 |
| Neomycin-Polymyxin-Hc | 16 | $765 | $48 |
| Omeprazole | 70 | $613 | $9 |
| Hydrocortisone | 69 | $414 | $6 |
| Prednisone | 45 | $213 | $5 |
| Cephalexin | 14 | $95 | $7 |
2015: 8 drugs
| Fluticasone Propionate | 166 | $2,460 | $15 |
| Neomycin-Polymyxin-Hc | 29 | $748 | $26 |
| Omeprazole | 50 | $594 | $12 |
| Nystatin | 26 | $503 | $19 |
| Prednisone | 47 | $294 | $6 |
| Famotidine | 15 | $246 | $16 |
| Hydrocortisone | 25 | $198 | $8 |
| Cephalexin | 15 | $111 | $7 |
2014: 10 drugs
| Nystatin-Triamcinolone | 59 | $6,351 | $108 |
| Fluticasone Propionate | 139 | $2,913 | $21 |
| Famotidine | 20 | $432 | $22 |
| Omeprazole | 41 | $338 | $8 |
| Neomycin-Polymyxin-Hc | 13 | $316 | $24 |
| Amox Tr-Potassium Clavulanate | 11 | $289 | $26 |
| Prednisone | 44 | $202 | $5 |
| Hydrocortisone | 25 | $169 | $7 |
| Hydrocodone-Acetaminophen | 17 | $169 | $10 |
| Cephalexin | 18 | $146 | $8 |
2013: 12 drugs
| Nystatin-Triamcinolone | 77 | $5,722 | $74 |
| Fluticasone Propionate | 116 | $2,812 | $24 |
| Omeprazole | 25 | $564 | $23 |
| Famotidine | 17 | $442 | $26 |
| Neomycin-Polymyxin-Hc | 22 | $439 | $20 |
| Prednisone | 64 | $327 | $5 |
| Cefuroxime | 11 | $311 | $28 |
| Mupirocin | 11 | $284 | $26 |
| Ciprofloxacin | 13 | $115 | $9 |
| Cephalexin | 14 | $79 | $6 |
| Hydrocodone-Acetaminophen | 17 | $77 | $5 |
| Levothyroxine | 12 | $55 | $5 |
Money from drug and device companies
$177 in 2025
| 2025 | 2 | 14 | None | $177 |
| 2024 | 4 | 20 | None | $316 |
| 2023 | 3 | 6 | None | $182 |
| 2022 | 1 | 1 | None | $40 |
| 2021 | 2 | 2 | None | $36 |
| 2020 | 4 | 10 | None | $229 |
| 2019 | 3 | 12 | None | $507 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | None | $157 | 13 payments
|
| Revance Therapeutics | Daxxify | $19 | 1 payment
|
See all 14 published payments
| Abbvie | Meals · 2025-10-25 | None | $8 |
| Abbvie | Meals · 2025-08-28 | None | $15 |
| Abbvie | Meals · 2025-07-09 | None | $14 |
| Abbvie | Education · 2025-06-18 | None | $10 |
| Abbvie | Education · 2025-06-18 | None | $10 |
| Abbvie | Meals · 2025-05-28 | None | $4 |
| Abbvie | Meals · 2025-05-28 | None | $14 |
| Abbvie | Meals · 2025-05-14 | None | $19 |
| Abbvie | Meals · 2025-05-13 | None | $15 |
| Abbvie | Meals · 2025-04-08 | None | $13 |
| Abbvie | Meals · 2025-03-06 | None | $15 |
| Abbvie | Meals · 2025-02-08 | None | $5 |
| Revance Therapeutics | Meals · 2025-01-20 | Daxxify | $19 |
| Abbvie | Meals · 2025-01-14 | None | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $316
| Abbvie | Botox | $140 | 11 payments
|
| Revance Therapeutics | Daxxify | $140 | 7 payments
|
| PolyNovo North America | Novosorb Btm | $19 | 1 payment
|
| Stryker | Essx | $17 | 1 payment
|
2023: $182
| Acclarent | Trudi Nav Cable | $86 | 2 payments
|
| Abbvie | None | $63 | 3 payments
|
| Stryker | Xpress Ent Dilation System | $33 | 1 payment
|
2022: $40
| Stryker | Xpress Ent Dilation System | $40 | 1 payment
|
2021: $36
| Allergan | Botox | $19 | 1 payment
|
| Stryker | Xpress Ent Dilation System | $17 | 1 payment
|
2020: $229
| Allergan | Botox Cosmetic | $176 | 7 payments
|
| Acclarent | Trudi Navigation System | $19 | 1 payment
|
| Ucb | Briviact | $17 | 1 payment
|
| Janssen Biotech | Stelara | $16 | 1 payment
|
2019: $507
| Allergan | Botox Cosmetic | $236 | 10 payments
|
| Galderma Laboratories L.P. | None | $146 | 1 payment
|
| Merz North America | None | $125 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 78.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1841203825
- Licence
- CA G83766California G83766: Current · expires 2029-01-31
- Trained
- Saint Louis University School of Medicine, 1992
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207YX0905X (207YX0905X)
- Mailing address
- 1921 Armondo Ct, Pleasanton, CA, 94566
- NPI first listed
- 2006-08-14
- NPI last updated
- 2016-03-07
This is when the NPI record was last certified, not a medical board exam.